NDAOPHTHALMICOINTMENT
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
ILOTYCIN (erythromycin) by Johnson & Johnson is clinical pharmacology orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. First approved in 1964.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOTYCIN (erythromycin) is a macrolide antibiotic ointment administered ophthalmically that treats bacterial infections including acne vulgaris, pneumonia, and blepharitis. It works by inhibiting protein synthesis through binding to the 50S ribosomal subunit of susceptible organisms.
LOE Approaching
Product approaching loss of exclusivity with limited commercial team investment expected; positions are typically defensive/maintenance focused.
Mechanism of Action
CLINICAL PHARMACOLOGY Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely…
Worked on ILOTYCIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.